



October 15, 2024

To The Listing Department <b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra - Kurla Complex Bandra (East) <u>Mumbai - 400 051</u> <i>Stock Code : INDOCO-EQ</i>	To The Listing Department <b>Bombay Stock Exchange Limited</b> Floor 25, P. J. Towers, Dalal Street, <u>Mumbai - 400 001</u> <i>Stock Code : 532612</i>
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

**Sub : Intimation of Earnings Conference Call on unaudited financial results for quarter and half year ended 30<sup>th</sup> September, 2024**

Pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that an Earnings Conference Call on Unaudited Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2024 is scheduled to be held on Thursday, 24<sup>th</sup> October, 2024 at 03:30 P.M. IST.

The details of the conference call are enclosed herewith.

This is for your information and dissemination on respective websites.

Thanking you,

Yours faithfully,

**For Indoco Remedies Limited**

**RAMANATHAN** Digitally signed by  
RAMANATHAN  
**N** HARIHARAN  
Date: 2024.10.15  
**HARIHARAN** 18:17:14 +05'30'  
**Ramanathan Hariharan**



**Company Secretary & Head Legal**



You are cordially invited to the  
Q2 FY25 Earnings Conference Call of  
**Indoco Remedies Limited**

on

Thursday, October 24, 2024 at 3:30PM IST

**Represented by:**

**Ms. Aditi Panandikar**  
**Mr. Sundeep V Bambolkar**  
**Mr. Pramod Ghorpade**

Managing Director  
Jt. Managing Director  
CFO

*Pre-register to avoid the waiting queue, join with DiamondPass link: [Registration Link](#)*

**Conference Dial-In Number**

**Universal Access**

+91 22 6280 1116  
+91 22 7115 8017

**International Toll Free**

**Hong Kong: 800 964 448**  
**Singapore: 800 101 2045**  
**USA: 1 866 746 2133**  
**UK: 0 808 101 1573**

For further information, please contact:

**Rashmi Shetty**  
VP - Research (Pharma)  
Dolat Capital Market Pvt. Ltd.  
(D) +91 22 40969724/8879111413  
Email: [rashmis@dolatcapital.com](mailto:rashmis@dolatcapital.com)

**Candice Pereira**  
Associate (Pharma)  
Dolat Capital Market Pvt. Ltd.  
(D) +91 22 40979633/9833458572  
Email: [candicep@dolatcapital.com](mailto:candicep@dolatcapital.com)

**Zain Gulam Hussain**  
Associate (Pharma)  
Dolat Capital Market Pvt. Ltd.  
(D) +91 22 40979790/9892724209  
Email: [zain@dolatcapital.com](mailto:zain@dolatcapital.com)